Inventiva SA ADR (IVA) has released an update.
Inventiva SA ADR recently announced the successful results of their Phase II LEGEND trial, which showed significant improvements in patients with MASH/NASH and Type 2 Diabetes (T2D) when treated with their drug lanifibranor, both alone and in combination with empagliflozin. The study met its primary efficacy endpoint by notably reducing HbA1c levels and demonstrated statistically significant benefits on various markers of liver injury and metabolism. Additionally, the combination therapy effectively stabilized patients’ weight and shifted body fat from harmful visceral to healthier subcutaneous distributions without raising safety concerns.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
